<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24586994</article-id><article-id pub-id-type="pmc">3934914</article-id><article-id pub-id-type="publisher-id">PONE-D-13-43321</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0089732</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group><subj-group><subject>Molecular Cell Biology</subject><subj-group><subject>Extracellular Matrix</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Cardiomyopathies</subject><subject>Cardiovascular Imaging</subject><subject>Heart Failure</subject></subj-group></subj-group><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The Effect of Rosuvastatin on Inflammation, Matrix Turnover and Left Ventricular Remodeling in Dilated Cardiomyopathy: A Randomized, Controlled Trial</article-title><alt-title alt-title-type="running-head">Rosuvastatin for Dilated Cardiomyopathy</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Broch</surname><given-names>Kaspar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Askevold</surname><given-names>Erik T.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gjertsen</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ueland</surname><given-names>Thor</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yndestad</surname><given-names>Arne</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Godang</surname><given-names>Kristin</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stueflotten</surname><given-names>Wenche</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Andreassen</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Svendsmark</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Hans-J&#x000f8;rgen</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aakhus</surname><given-names>Svend</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aukrust</surname><given-names>P&#x000e5;l</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gullestad</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Endocrinology, Oslo University Hospital Rikshospitalet, Oslo, Norway</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust; Drammen, Norway</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Faculty of Medicine, University of Oslo, Oslo, Norway</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gupta</surname><given-names>Sudhiranjan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Texas A &#x00026; M, Division of Cardiology, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>kaspar.broch@ous-hf.no</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>This work was supported by AstraZeneca&#x000ae;, providing an unrestricted grant and the active drug and placebo tablets used in this study. Dr Gjertsen has received lecture fees from AstraZeneca&#x000ae;. In addition, the authors would like to state that 1) No research cost or salaries relevant to this work were funded, in whole or in part, by a tobacco company; 2) The anonymous donor has no competing interest in relation to this work; 3) The identity of the anonymous donor, as disclosed in an e-mail to the editorial office, is not relevant to the editors or the reviewers' assessment of the current work; 4) The authors are not aware of any competing interests. None of the above revisions/statements alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: ETA TU AY H-JS SA PA LG. Performed the experiments: KB ETA EG WS JA LG. Analyzed the data: KB TU AY KG JA RS. Contributed reagents/materials/analysis tools: TU AY KG. Wrote the paper: KB PA LG.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2014</year></pub-date><volume>9</volume><issue>2</issue><elocation-id>e89732</elocation-id><history><date date-type="received"><day>4</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Broch et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Broch et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Dilated cardiomyopathy is characterized by left ventricular dilatation and dysfunction. Inflammation and adverse remodeling of the extracellular matrix may be involved in the pathogenesis. Statins reduce levels of low density lipoprotein cholesterol, but may also attenuate inflammation and affect matrix remodeling. We hypothesized that treatment with rosuvastatin would reduce or even reverse left ventricular remodeling in dilated cardiomyopathy.</p></sec><sec><title>Materials and Methods</title><p>In this multicenter, randomized, double blind, placebo-controlled study, 71 patients were randomized to 10 mg of rosuvastatin or matching placebo. Physical examination, blood sampling, echocardiography and cardiac magnetic resonance imaging were performed at baseline and at six months&#x02019; follow-up. The pre-specified primary end point was the change in left ventricular ejection fraction from baseline to six months.</p></sec><sec><title>Results</title><p>Over all, left ventricular ejection fraction improved 5 percentage points over the duration of the study, but there was no difference in the change in left ventricular ejection fraction between patients allocated to rosuvastatin and those allocated to placebo. Whereas serum low density lipoprotein cholesterol concentration fell significantly in the treatment arm, rosuvastatin did not affect plasma or serum levels of a wide range of inflammatory variables, including C-reactive protein. The effect on markers of extracellular matrix remodeling was modest.</p></sec><sec><title>Conclusion</title><p>Treatment with rosuvastatin does not improve left ventricular ejection fraction in patients with dilated cardiomyopathy.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00505154">NCT00505154</ext-link>
</p></sec></abstract><funding-group><funding-statement>The trial was supported by an unrestricted grant from AstraZeneca&#x000ae;. The trial was also sponsored by an anonymous donor. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Statins are inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis. Statins significantly reduce the risk of coronary events in patients with, or at risk of developing, coronary artery disease <xref rid="pone.0089732-Randomised1" ref-type="bibr">[1]</xref>
<xref rid="pone.0089732-Ridker1" ref-type="bibr">[2]</xref>. While these effects are clearly related to lipid lowering, statins also possess anti-inflammatory and matrix stabilizing properties of potential relevance to their cardioprotective effects <xref rid="pone.0089732-Mihos1" ref-type="bibr">[3]</xref>. The relative risk reduction observed in statin trials is independent of baseline cholesterol levels <xref rid="pone.0089732-Randomised1" ref-type="bibr">[1]</xref> and is associated with a treatment-induced reduction of C-reactive protein (CRP) serum concentration <xref rid="pone.0089732-Ridker2" ref-type="bibr">[4]</xref>.</p><p>The role of statins in heart failure (HF) has been under debate. Two major, randomized controlled trials in patients with HF, the CORONA <xref rid="pone.0089732-Kjekshus1" ref-type="bibr">[5]</xref> and GISSI-HF <xref rid="pone.0089732-Tavazzi1" ref-type="bibr">[6]</xref> trials, did not show any effect on survival with treatment with rosuvastatin, a statin that effectively reduces the number of coronary events in a low risk population <xref rid="pone.0089732-Ridker1" ref-type="bibr">[2]</xref>. However, in several small, randomized trials, treatment with a statin has been associated with improved left ventricular (LV) function and a reduction in markers of inflammation in patients with dilated cardiomyopathy (DCM) <xref rid="pone.0089732-Node1" ref-type="bibr">[7]</xref>
<xref rid="pone.0089732-Sola1" ref-type="bibr">[8]</xref>
<xref rid="pone.0089732-Wojnicz1" ref-type="bibr">[9]</xref>
<xref rid="pone.0089732-BieleckaDabrowa1" ref-type="bibr">[10]</xref>. A meta-analysis, including the CORONA and GISSI trials, recently concluded that there is evidence to suggest that in patients with HF, statins may improve LV ejection fraction (LVEF) and reduce the number of hospitalizations for worsening HF <xref rid="pone.0089732-Lipinski1" ref-type="bibr">[11]</xref>. It is unclear, however, if these effects are related to changes in immunological parameters or remodeling of the extracellular matrix.</p><p>Approximately 10% of HF cases are due to DCM <xref rid="pone.0089732-Cleland1" ref-type="bibr">[12]</xref>. Dilated cardiomyopathy is a clinical entity based on morphological criteria and exclusion of specific causes of LV dysfunction such as coronary artery disease, valvular disease or hypertension <xref rid="pone.0089732-Elliott1" ref-type="bibr">[13]</xref>. This phenotype is probably the result of a multifactorial process where external or internal stressors induce structural changes in the myocardium of individuals at risk. Dilated cardiomyopathy may thus serve as a model for studying pathogenic mechanisms in the failing myocardium <italic>per se,</italic> without one having to account for the confounding effect of coronary atherosclerosis. In the present study, we evaluated the effect of rosuvastatin in patients with idiopathic DCM, hypothesizing that rosuvastatin would reduce or even reverse LV remodeling in this patient population through effects on inflammation and matrix remodeling.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Study Procedures</title><p>This is a multicenter, randomized, double blind, placebo-controlled trial designed to assess the effect of rosuvastatin on LV function in patients with DCM (ClinicalTrials.gov, registration number NCT00505154; <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00505154">http://clinicaltrials.gov/ct2/show/NCT00505154</ext-link>). It was conducted at three sites in Norway. The investigation conforms with the principles outlined in the Declaration of Helsinki and was approved by the Regional Committee for Medical and Health Research Ethics South East and the Norwegian Medicines Agency. All patients provided written, informed consent. The study was performed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement <xref rid="pone.0089732-Schulz1" ref-type="bibr">[14]</xref>. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0089732.s002">Protocol S1</xref> and <xref ref-type="supplementary-material" rid="pone.0089732.s001">Checklist S1</xref>.</p><p>At baseline, all participants underwent physical examination, blood tests, echocardiography and, unless contraindicated, cardiac magnetic resonance imaging (MRI). Patients were then randomized to 10 mg of rosuvastatin or matching placebo, once daily, in a 1:1 fashion. After four weeks and three months, the patients were reassessed for safety. Physical examination, blood tests, echocardiography and cardiac MRI were repeated after six months of intervention.</p></sec><sec id="s2b"><title>Patient population</title><p>Patients between 18 and 80 years old with symptoms and/or signs of HF for at least three months and with LVEF &#x02264; 40% were eligible, provided that treatment with a cholesterol-lowering drug was not otherwise indicated. Criteria for exclusion included decompensated HF requiring mechanical or inotropic support; HF of ischemic etiology; hemodynamically significant valvular disease not considered to be secondary to ventricular dilatation; recent or planned surgical procedures or operations; significant concomitant disease such as infection, severe pulmonary disease or connective tissue disease; acute or chronic liver disease; current statin treatment; or contraindications to statin therapy defined as hypersensitivity to any statin, alanine transaminase &#x02265; 2 times the upper limit of normal, serum creatinine &#x02265; 2 mg/dL, an unexplained creatine kinase &#x02265; 3 times the upper limit of normal, current or planned pregnancy, or breast feeding.</p></sec><sec id="s2c"><title>Drug handling, randomization and blinding</title><p>Rosuvastatin and matching placebo tablets were provided by the manufacturer (AstraZeneca) and appropriately stored. A randomization list was produced by an external department by computer block randomization and placed in a concealed envelope. Study drugs were provided in numbered, otherwise indistinguishable containers and dispensed in a double blind fashion by a dedicated study nurse. Study drug adherence was evaluated at one, three and six months&#x02019; follow-up based on pill counts of returned, unused study medication. Compliance was considered good if more than 80% of the appropriate number of tablets had been taken.</p></sec><sec id="s2d"><title>Study outcomes</title><p>The primary objective of this study was to evaluate the effect of rosuvastatin on LV remodeling in patients with HF due to idiopathic DCM. The pre-specified primary end point was the change in LVEF from baseline to follow-up as analyzed by MRI. Due to the fact that many otherwise eligible patients had contraindications to cardiac MRI, we chose to report the change in LVEF as determined by MRI or, if the latter result was not available at both baseline and follow-up, by echocardiography. Secondary endpoints were effects on neurohormonal variables, immunological variables and markers of extracellular matrix remodeling; LV end-diastolic and end-systolic volumes as measured by MRI and echocardiography; New York Heart Association (NYHA) functional class; and quality of life. Withdrawals and side effects were recorded.</p></sec><sec id="s2e"><title>Imaging</title><p>MRI and echocardiography were performed at baseline, before study drug administration, and after six months, prior to study drug discontinuation. All image analyses were performed at Oslo University Hospital, Rikshospitalet, which served as the core laboratory. Image analyses were performed by operators blinded to patient treatment allocation.</p></sec><sec id="s2f"><title>Magnetic resonance imaging</title><p>Siemens 1.5 tesla scanners were used for MRI (Siemens Avanto and Siemens Sonata; Siemens Medical Systems, Erlangen, Germany). LV long axis and short axis views were acquired using a breath-hold, prospectively ECG-triggered, segmented, balanced, steady-state free precession gradient-echo cine sequence with minimum echo and repetition times, 6 mm slice thickness, 4 mm short-axis interslice gap, spatial resolution 1.9 mm&#x000d7;1.3 mm, and temporal resolution 30&#x02013;35ms. LV endocardial borders were traced manually using a PACS work station (Sectra Medical Systems AB, Link&#x000f6;ping, Sweden), and LV volumes and ejection fractions were calculated by short axis slice summation.</p></sec><sec id="s2g"><title>Echocardiography</title><p>Echocardiography was performed with Vivid 7 or E9 ultrasound scanners (GE Vingmed Ultrasound, Horten, Norway), using phased array transducers. Cine loops were digitally stored and later analyzed off line using Echo-Pac (GE Vingmed). 2D parameters and conventional Doppler parameters were measured according to current recommendations <xref rid="pone.0089732-Lang1" ref-type="bibr">[15]</xref>
<xref rid="pone.0089732-Galderisi1" ref-type="bibr">[16]</xref>. Valvular regurgitations were graded as mild, moderate or severe by visual assessment <xref rid="pone.0089732-Rivera1" ref-type="bibr">[17]</xref>. LVEF was measured by Simpson&#x02019;s biplane method <xref rid="pone.0089732-Lang1" ref-type="bibr">[15]</xref>.</p></sec><sec id="s2h"><title>Blood sampling</title><p>Peripheral blood was collected in pyrogen-free tubes without any additives (serum) or with EDTA as anticoagulant (plasma). The tubes were allowed to coagulate at room temperature (serum) or put on melting ice (plasma) and centrifuged after coagulation (1000<italic>g</italic> at 10 minutes) or within 10 minutes (2000 <italic>g</italic> at 20 minutes) to obtain serum and platelet-poor plasma, respectively. Serum and plasma samples were stored at &#x02013;80&#x000b0;C in multiple aliquots and thawed once only.</p></sec><sec id="s2i"><title>Biochemical analyses</title><p>N-terminal pro-B-type natriuretic peptide (NT-proBNP) was analyzed by routine methods on a MODULAR analytical platform by an electrochemiluminescence immunoassay (Roche proBNP II, Roche Diagnostic, Basel, Switzerland). Levels of CRP were determined on a MODULAR Analytical platform, P800 module (Roche Diagnostics) using a particle-enhanced immunoturbidimetric assay (Tina-Quant CRP Gen.3). Soluble tumor necrosis factor receptor type 1 (sTNF-R1), osteoprotegerin (OPG), soluble glycoprotein 130 (sgp130), matrix metalloproteinase-9 (MMP-9) and monocyte chemotactic protein-1 (MCP-1)/CCL2 were analyzed by enzyme immunoassays obtained from R&#x00026;D Systems (Minneapolis, MN).</p><p>Procollagen type I and III N-terminal pro-peptides (PINP and PIIINP, respectively) were analyzed by radioimmunoassays (UniQ PINP RIA and UniQ PIIINP RIA, Orion Diagnostica, Espoo, Finland). Von Willebrand factor (vWF) was determined by an enzyme immunoassay as previously reported <xref rid="pone.0089732-Bollerslev1" ref-type="bibr">[18]</xref>. Inter-and intra-assay coefficients of variation were &#x0003c; 10% for all biochemical analyses.</p></sec><sec id="s2j"><title>Quality of life assessment</title><p>Quality of life was assessed at baseline and after six months using self-report inventories. Heart failure related symptoms were measured with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the EuroQol visual analogue scale. Symptoms of depression were assessed using the Beck Depression Inventory.</p></sec><sec id="s2k"><title>Statistics</title><p>Assuming a standard deviation of 7.5% in LVEF measurement, we calculated that with an &#x003b1; of 5% and power of 80% we would need 32 patients in each group in order to observe a 5 per cent points difference in the change in LVEF between the rosuvastatin and placebo arms at follow-up. To allow for drop out, we aimed to enroll 75 patients.</p><p>To assess total population differences between baseline and follow-up, we used paired parametric (t-tests) or non-parametric (Wilcoxon signed rank) tests depending on distribution. Differences in numerical outcome variables between patients treated with rosuvastatin and patients treated with placebo were analyzed using analysis of covariance (ANCOVA), adjusting for baseline values <xref rid="pone.0089732-Vickers1" ref-type="bibr">[19]</xref>. Highly skewed parameters were log transformed prior to analysis. The number of adverse events was compared across treatment groups by Poisson regression. The between-group difference in the change in NYHA class from baseline to follow-up was analyzed by general estimating equations. All end point analyses were performed according to the intention-to-treat principle. Numerical values are presented as mean values &#x000b1; SD or median (interquartile range) as appropriate. All statistical analyses were performed with the Statistical Package for Social Sciences version 18 software (SPSS Inc. Chicago, IL). Two-sided probability values were considered significant at p &#x0003c; 0.05.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patients</title><p>From the 20<sup>th</sup> of September 2007 to the 15<sup>th</sup> of February 2012, a total of 72 patients were included in Oslo (n &#x0200a;=&#x0200a; 57), Drammen (n &#x0200a;=&#x0200a; 12) and Trondheim (n &#x0200a;=&#x0200a; 3). A DCM phenotype had been confirmed by echocardiography prior to inclusion. Ischemic etiology had been excluded by a combination of patient history, coronary angiography (n &#x0200a;=&#x0200a; 71) and/or myocardial scintigraphy. Primary valvular disease was excluded by a combination of patient history and echocardiography. For administrative reasons, one patient was never randomized and was excluded from further participation in the study. Seventy-one patients were thus randomized, of whom 36 were allocated to treatment with rosuvastatin and 35 to placebo. Baseline characteristics stratified by treatment allocation are presented in <xref ref-type="table" rid="pone-0089732-t001">Table 1</xref>. Sixty seven patients were na&#x000ef;ve to statins, whereas five patients had stopped taking statins 5 &#x02013; 61 months prior to inclusion. Throughout the study period, heart failure treatment was adjusted in an individualized fashion according to current guidelines <xref rid="pone.0089732-Dickstein1" ref-type="bibr">[20]</xref>. One patient discontinued study drug treatment after 5 days and was later lost to follow up. One patient withdrew consent without stating any particular reason. Both of these patients were in the rosuvastatin arm. A total of 69 patients were thus re-evaluated after 182&#x000b1;20 days. In one patient, imaging data were incomplete, and this patient was excluded from analysis of the primary endpoint (<xref ref-type="fig" rid="pone-0089732-g001">Figure 1</xref>).</p><fig id="pone-0089732-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.g001</object-id><label>Figure 1</label><caption><title>Trial flow chart.</title></caption><graphic xlink:href="pone.0089732.g001"/></fig><table-wrap id="pone-0089732-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.t001</object-id><label>Table 1</label><caption><title>Baseline data stratified according to treatment allocation.</title></caption><alternatives><graphic id="pone-0089732-t001-1" xlink:href="pone.0089732.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" rowspan="1" colspan="1">Rosuvastatin (N &#x0200a;=&#x0200a; 36)</td><td align="left" rowspan="1" colspan="1">Placebo (N &#x0200a;=&#x0200a; 35)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Clinical characteristics</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age - years</td><td align="left" rowspan="1" colspan="1">58&#x000b1;11</td><td align="left" rowspan="1" colspan="1">58&#x000b1;11</td><td align="left" rowspan="1" colspan="1">58&#x000b1;11</td></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">55 (78)</td><td align="left" rowspan="1" colspan="1">27 (75)</td><td align="left" rowspan="1" colspan="1">28 (80)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="left" rowspan="1" colspan="1">28&#x000b1;5</td><td align="left" rowspan="1" colspan="1">28&#x000b1;5</td><td align="left" rowspan="1" colspan="1">28&#x000b1;5</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure - mm Hg</td><td align="left" rowspan="1" colspan="1">125&#x000b1;20</td><td align="left" rowspan="1" colspan="1">128&#x000b1;23</td><td align="left" rowspan="1" colspan="1">123&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure - mm Hg</td><td align="left" rowspan="1" colspan="1">77&#x000b1;10</td><td align="left" rowspan="1" colspan="1">77&#x000b1;11</td><td align="left" rowspan="1" colspan="1">76&#x000b1;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate &#x02013; beats/minute</td><td align="left" rowspan="1" colspan="1">67&#x000b1;12</td><td align="left" rowspan="1" colspan="1">66&#x000b1;11</td><td align="left" rowspan="1" colspan="1">69&#x000b1;13</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">15 (21)</td><td align="left" rowspan="1" colspan="1">3 (8)</td><td align="left" rowspan="1" colspan="1">12 (34)</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class I &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">8 (11)</td><td align="left" rowspan="1" colspan="1">4 (11)</td><td align="left" rowspan="1" colspan="1">4 (11)</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class II &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">43 (62)</td><td align="left" rowspan="1" colspan="1">21 (58)</td><td align="left" rowspan="1" colspan="1">22 (63)</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class III &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">20 (28)</td><td align="left" rowspan="1" colspan="1">11 (31)</td><td align="left" rowspan="1" colspan="1">9 (26)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Medical history</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smokers &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">13 (18)</td><td align="left" rowspan="1" colspan="1">6 (17)</td><td align="left" rowspan="1" colspan="1">7 (20)</td></tr><tr><td align="left" rowspan="1" colspan="1">History of hypertension &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">21 (30)</td><td align="left" rowspan="1" colspan="1">17 (47)</td><td align="left" rowspan="1" colspan="1">4 (11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">10 (14)</td><td align="left" rowspan="1" colspan="1">7 (19)</td><td align="left" rowspan="1" colspan="1">3 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior stroke/TIA &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">2 (3)</td><td align="left" rowspan="1" colspan="1">1 (3)</td><td align="left" rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Baseline medication</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ACEI and/or ARB no (%)</td><td align="left" rowspan="1" colspan="1">71 (100)</td><td align="left" rowspan="1" colspan="1">36 (100)</td><td align="left" rowspan="1" colspan="1">35 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta blocker &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">70 (99)</td><td align="left" rowspan="1" colspan="1">35 (97)</td><td align="left" rowspan="1" colspan="1">35 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aldosterone antagonist &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">30 (42)</td><td align="left" rowspan="1" colspan="1">18 (50)</td><td align="left" rowspan="1" colspan="1">12 (34)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diuretic &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">49 (69)</td><td align="left" rowspan="1" colspan="1">26 (72)</td><td align="left" rowspan="1" colspan="1">23 (66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Digoxin or digitoxin &#x02013; no (%)</td><td align="left" rowspan="1" colspan="1">13 (18)</td><td align="left" rowspan="1" colspan="1">5 (14)</td><td align="left" rowspan="1" colspan="1">8 (23)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Laboratory values</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mmol/l) [mg/dl]</td><td align="left" rowspan="1" colspan="1">85&#x000b1;19 [0.96&#x000b1;0.21]</td><td align="left" rowspan="1" colspan="1">86&#x000b1;18 [0.97&#x000b1;0.21]</td><td align="left" rowspan="1" colspan="1">84&#x000b1;20.[0.95&#x000b1;0.22]</td></tr><tr><td align="left" rowspan="1" colspan="1">Total serum cholesterol &#x02013; mmol/l</td><td align="left" rowspan="1" colspan="1">5.8&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">C-reactive protein &#x02013; mg/l</td><td align="left" rowspan="1" colspan="1">2.2 (1.0&#x02013;5.3)</td><td align="left" rowspan="1" colspan="1">1.7 (1.0&#x02013;1.4)</td><td align="left" rowspan="1" colspan="1">2.7 (1.3&#x02013;6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">N-terminal pro-B-type natriuretic peptide &#x02013; pg/dl</td><td align="left" rowspan="1" colspan="1">592 (236&#x02013;1607)</td><td align="left" rowspan="1" colspan="1">600 (186&#x02013;1630)</td><td align="left" rowspan="1" colspan="1">588 (243&#x02013;1643)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>NYHA: New York Heart Association; TIA: transient ischemic attack; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Left ventricular remodeling and function</title><p>Magnetic resonance imaging was performed in 53 patients at baseline. Thirteen patients had an implantable device prohibiting cardiac MRI, in one patient MRI was contraindicated due to anxiety, and in three patients, MRI was not performed for administrative reasons. Fifty of the patients in whom MRI was performed at baseline, also had an MRI at six months&#x02019; follow-up. Echocardiographic images were available for all participants who were not lost to follow up, but in four patients, echocardiographic image quality did not allow for quantification of LVEF. In 68 patients, 34 in the rosuvastatin group and 34 in the placebo group, LVEF was available by MRI and/or echocardiography at baseline as well as follow-up.</p><p>Over all, LVEF improved 4.6 percentage points over the duration of the study (95% confidence interval 2.2&#x02013;7.0; p &#x0003c; 0.001), but there was no difference in the adjusted LVEF between the two treatment groups after six months (<xref ref-type="fig" rid="pone-0089732-g002">Figure 2</xref> and <xref ref-type="table" rid="pone-0089732-t002">Table 2</xref>). The two treatment groups were well balanced for baseline characteristics. However, there was a four times higher proportion of previously hypertensive patients in the rosuvastatin arm, and a four times higher proportion of patients with atrial fibrillation in the placebo arm. Adjusting for these differences did not affect the main result. A similar pattern as for LVEF was seen for LV end diastolic and end systolic size; despite a reduction in volumes across both treatment arms, there was no between-group difference in the outcome (<xref ref-type="table" rid="pone-0089732-t002">Table 2</xref>). Results obtained by cardiac MRI and echocardiography were highly congruous (<xref ref-type="fig" rid="pone-0089732-g003">Figure 3</xref>).</p><fig id="pone-0089732-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.g002</object-id><label>Figure 2</label><caption><title>Changes in left ventricular ejection fraction and LDL cholesterol.</title><p>The left panel illustrates the change in left ventricular ejection fraction (LVEF) stratified by treatment allocation. There was no difference in the change in LVEF between the two groups as analyzed by an independent group t-test (p &#x0200a;=&#x0200a; 0.94). The right panel illustrates the change in LDL cholesterol stratified by treatment allocation. The fall in LDL cholesterol occurred in patients allocated to rosuvastatin (p for difference &#x0003c; 0.001). Boxes: 25&#x02013;75 percentiles; whiskers: 10&#x02013;90 percentiles.</p></caption><graphic xlink:href="pone.0089732.g002"/></fig><fig id="pone-0089732-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.g003</object-id><label>Figure 3</label><caption><title>Correlation between left ventricular ejection fraction as measured by echocardiography and as measured by magnetic resonance imaging.</title><p>Data from baseline and follow-up are pooled. The Pearson correlation coefficient between results obtained by magnetic resonance imaging (MRI) and results obtained by echocardiography was 0.82 (p &#x0003c; 0.001).</p></caption><graphic xlink:href="pone.0089732.g003"/></fig><table-wrap id="pone-0089732-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.t002</object-id><label>Table 2</label><caption><title>Results from cardiac imaging exams, New York Heart Association (NYHA) classification and quality of life measurements.</title></caption><alternatives><graphic id="pone-0089732-t002-2" xlink:href="pone.0089732.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td colspan="3" align="left" rowspan="1">Placebo</td><td colspan="3" align="left" rowspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">p-value for between-group difference</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Change (95% CI)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Change (95% CI)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Imaging</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)<xref ref-type="table-fn" rid="nt102">*</xref>
</td><td align="left" rowspan="1" colspan="1">36&#x000b1;13</td><td align="left" rowspan="1" colspan="1">40&#x000b1;14</td><td align="left" rowspan="1" colspan="1">4.7 (0.9 &#x02013; 8.5)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">36&#x000b1;13</td><td align="left" rowspan="1" colspan="1">41&#x000b1;15</td><td align="left" rowspan="1" colspan="1">4.5 (1.5 &#x02013; 7.5)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">EDV by MRI (ml)</td><td align="left" rowspan="1" colspan="1">249 (185 &#x02013; 325)</td><td align="left" rowspan="1" colspan="1">202 (160 &#x02013; 303)</td><td align="left" rowspan="1" colspan="1">&#x02013;36 (&#x02013;61 &#x02013; &#x02013;10)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">242 (191 &#x02013; 326)</td><td align="left" rowspan="1" colspan="1">193 (169 &#x02013; 326)</td><td align="left" rowspan="1" colspan="1">&#x02013;26 (&#x02013;48 &#x02013; &#x02013;3)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">ESV by MRI (ml)</td><td align="left" rowspan="1" colspan="1">159 (93 &#x02013; 242)</td><td align="left" rowspan="1" colspan="1">118 (79&#x02013;216)</td><td align="left" rowspan="1" colspan="1">&#x02013;35 (&#x02013;60 &#x02013; &#x02013;9)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">154 (92 &#x02013; 236)</td><td align="left" rowspan="1" colspan="1">102 (67 &#x02013; 176)</td><td align="left" rowspan="1" colspan="1">&#x02013;28 (&#x02013;49 &#x02013; &#x02013;7)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF by MRI (%)</td><td align="left" rowspan="1" colspan="1">36&#x000b1;14</td><td align="left" rowspan="1" colspan="1">41&#x000b1;15</td><td align="left" rowspan="1" colspan="1">5.4 (0.9 &#x02013; 9.9)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">38&#x000b1;14</td><td align="left" rowspan="1" colspan="1">44&#x000b1;15</td><td align="left" rowspan="1" colspan="1">5.8 (2.0 &#x02013; 9.5)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">EDV by E/D (ml)</td><td align="left" rowspan="1" colspan="1">188 (141 &#x02013; 228)</td><td align="left" rowspan="1" colspan="1">151 (134 &#x02013; 210)</td><td align="left" rowspan="1" colspan="1">&#x02013;19 (&#x02013;32 &#x02013; &#x02013;7)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">202 (145 &#x02013; 278)</td><td align="left" rowspan="1" colspan="1">186 (138 &#x02013; 270)</td><td align="left" rowspan="1" colspan="1">&#x02013;2 (&#x02212;17 &#x02013; 13)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">ESV by E/D (ml)</td><td align="left" rowspan="1" colspan="1">129 (87 &#x02013; 165)</td><td align="left" rowspan="1" colspan="1">95 (79 &#x02013; 148)</td><td align="left" rowspan="1" colspan="1">&#x02013;19 (&#x02013;32 &#x02013; &#x02013;6)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">135 (99 &#x02013; 203)</td><td align="left" rowspan="1" colspan="1">126 (78 &#x02013; 204)</td><td align="left" rowspan="1" colspan="1">&#x02013;6 (&#x02212;20 &#x02013; 7)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF by E/D (%)</td><td align="left" rowspan="1" colspan="1">32&#x000b1;10</td><td align="left" rowspan="1" colspan="1">36&#x000b1;10</td><td align="left" rowspan="1" colspan="1">3.9 (1.0 &#x02013; 6.6)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">31&#x000b1;8</td><td align="left" rowspan="1" colspan="1">34&#x000b1;11</td><td align="left" rowspan="1" colspan="1">3.7 (0.9 &#x02013; 6.6)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>NYHA class</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NYHA class (I/II/III)</td><td align="left" rowspan="1" colspan="1">4/22/9</td><td align="left" rowspan="1" colspan="1">7/22/6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4/21/11</td><td align="left" rowspan="1" colspan="1">5/26/3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Quality of life</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MLHFQ</td><td align="left" rowspan="1" colspan="1">23 (4 &#x02013; 35)</td><td align="left" rowspan="1" colspan="1">14 (3 &#x02013; 23)</td><td align="left" rowspan="1" colspan="1">&#x02013;3 (&#x02212;9 &#x02013; 2)</td><td align="left" rowspan="1" colspan="1">30 (16 &#x02013; 56)</td><td align="left" rowspan="1" colspan="1">20 (9 &#x02013; 44)</td><td align="left" rowspan="1" colspan="1">&#x02013;7 (&#x02212;12 &#x02013; &#x02013;1)<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Beck depression inventory</td><td align="left" rowspan="1" colspan="1">4 (2 &#x02013; 7)</td><td align="left" rowspan="1" colspan="1">3 (1 &#x02013; 5)</td><td align="left" rowspan="1" colspan="1">&#x02013;1 (&#x02212;2 &#x02013; 0)</td><td align="left" rowspan="1" colspan="1">6 (2 &#x02013; 9)</td><td align="left" rowspan="1" colspan="1">3 (1 &#x02013; 9)</td><td align="left" rowspan="1" colspan="1">&#x02013;1 (&#x02212;3 &#x02013; 0)</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroQoL VAS (%)</td><td align="left" rowspan="1" colspan="1">66&#x000b1;17</td><td align="left" rowspan="1" colspan="1">68&#x000b1;15</td><td align="left" rowspan="1" colspan="1">2 (&#x02212;4 &#x02013; 7)</td><td align="left" rowspan="1" colspan="1">64&#x000b1;18</td><td align="left" rowspan="1" colspan="1">66&#x000b1;18</td><td align="left" rowspan="1" colspan="1">1 (&#x02212;7 &#x02013; 8)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>*This row represents left ventricular ejection fraction (LVEF) by magnetic resonance imaging (MRI) or, if the latter result was not available at both baseline and follow-up, LVEF by echocardiography (E/D, N&#x0200a;=&#x0200a;18). <sup>&#x02020;</sup> p &#x0003c; 0.05 for difference between baseline and follow-up. CI: confidence interval; EDV: end diastolic left ventricular internal volume; ESV: end systolic left ventricular internal volume; NT-proBNP: N-terminal pro-B-type natriuretic peptide; LDL: low density lipoprotein; MLHFQ: Minnesota Living with Heart Failure Questionnaire; VAS: visual analogue scale.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Lipids and markers of inflammation, endothelial reactivity and extracellular matrix turnover</title><p>Laboratory results are presented in <xref ref-type="table" rid="pone-0089732-t003">Table 3</xref>. Consistent with a high level of adherence to the study drug regimen, a substantial reduction in total and LDL cholesterol was observed in patients treated with rosuvastatin, resulting in a highly significant between-group difference (<xref ref-type="fig" rid="pone-0089732-g002">Figure 2</xref> and <xref ref-type="table" rid="pone-0089732-t003">table 3</xref>). In contrast, markers of inflammation, i.e. CRP, sTNF-R1, MCP1, sgp130 and OPG <xref rid="pone.0089732-Gullestad1" ref-type="bibr">[21]</xref> and endothelial reactivity (vWF) <xref rid="pone.0089732-Constans1" ref-type="bibr">[22]</xref> remained essentially unchanged throughout the study, and no difference was observed between treatment groups (<xref ref-type="table" rid="pone-0089732-t003">Table 3</xref> and <xref ref-type="fig" rid="pone-0089732-g004">Figure 4</xref>).</p><fig id="pone-0089732-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.g004</object-id><label>Figure 4</label><caption><title>Changes in markers of inflammation and extracellular matrix turnover.</title><p>Changes in C-reactive protein (CRP), soluble tumor necrosis factor receptor type 1 (sTNF-R1), and procollagen type I and III N-terminal pro-peptides (PINP and PIIINP) stratified by treatment allocation. p-values for between-group differences in changes were computed by independent group t-tests. While PINP increased more in patients treated with rosuvastatin as compared to patients treated with placebo (p &#x0200a;=&#x0200a; 0.03), treatment did not affect any of the other markers of inflammation or matrix remodeling. Boxes: 25&#x02013;75 percentiles; whiskers: 5&#x02013;95 percentiles.</p></caption><graphic xlink:href="pone.0089732.g004"/></fig><table-wrap id="pone-0089732-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0089732.t003</object-id><label>Table 3</label><caption><title>Results of blood tests.</title></caption><alternatives><graphic id="pone-0089732-t003-3" xlink:href="pone.0089732.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td colspan="3" align="left" rowspan="1">Placebo</td><td colspan="3" align="left" rowspan="1">Rosuvastatin</td><td align="left" rowspan="1" colspan="1">p-value for between- group difference</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Change (95% CI)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Change (95% CI)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Lipids</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.3 &#x02013; 0.2)</td><td align="left" rowspan="1" colspan="1">5.9&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">4.3&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.1 &#x02212; &#x02212;1.3)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">3.7&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">3.6&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.2 &#x02212; 0.1)</td><td align="left" rowspan="1" colspan="1">3.8&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">2.1&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;2.0 &#x02212; &#x02212;1.4)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.2&#x000b1;0.3</td><td align="left" rowspan="1" colspan="1">1.2&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0 (&#x02212;0.1 &#x02212; 0.1)</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">0.1 (0 &#x02212; 0.2)</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Natriuretic peptides</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NT-ProBNP (pg/dl)</td><td align="left" rowspan="1" colspan="1">617 (245 &#x02212; 1581)</td><td align="left" rowspan="1" colspan="1">499 (167 &#x02212; 1226)</td><td align="left" rowspan="1" colspan="1">&#x02212;79 (&#x02212;347 &#x02212; 307)</td><td align="left" rowspan="1" colspan="1">567 (186 &#x02212; 1615)</td><td align="left" rowspan="1" colspan="1">431 (169 &#x02212; 983)</td><td align="left" rowspan="1" colspan="1">&#x02212;19 (&#x02212;418 &#x02212; 475)</td><td align="left" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Kidney function</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x000b5;mol/l) [mg/dl]</td><td align="left" rowspan="1" colspan="1">84&#x000b1;20</td><td align="left" rowspan="1" colspan="1">82&#x000b1;14</td><td align="left" rowspan="1" colspan="1">&#x02212;2 (&#x02212;6 &#x02212; 3)</td><td align="left" rowspan="1" colspan="1">86&#x000b1;18</td><td align="left" rowspan="1" colspan="1">86&#x000b1;18</td><td align="left" rowspan="1" colspan="1">1 (&#x02212;2 &#x02212; 3)</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Markers of inflammation</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">C&#x02212;reactive protein (mg/l)</td><td align="left" rowspan="1" colspan="1">2.7 (1.3 &#x02212; 6.2)</td><td align="left" rowspan="1" colspan="1">3.2 (1.2 &#x02212; 10.1)</td><td align="left" rowspan="1" colspan="1">1.1 (&#x02212;1.3 &#x02212; 3.5)</td><td align="left" rowspan="1" colspan="1">1.7 (1.0 &#x02212; 4.0)</td><td align="left" rowspan="1" colspan="1">2.1 (1.0 &#x02212; 4.9)</td><td align="left" rowspan="1" colspan="1">1.2 (&#x02212;1.1 &#x02212; 3.4)</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">sTNF-R1 (pg/ml)</td><td align="left" rowspan="1" colspan="1">1039&#x000b1;271</td><td align="left" rowspan="1" colspan="1">1038 &#x000b1; 304</td><td align="left" rowspan="1" colspan="1">&#x02212;1 (&#x02212;71 &#x02013; 68)</td><td align="left" rowspan="1" colspan="1">1134&#x000b1;327</td><td align="left" rowspan="1" colspan="1">1082 &#x000b1; 235</td><td align="left" rowspan="1" colspan="1">&#x02212;53 (&#x02212;141 &#x02013; 36)</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">MCP-1 (pg/ml)</td><td align="left" rowspan="1" colspan="1">115 (72 &#x02013; 160)</td><td align="left" rowspan="1" colspan="1">117 (76 &#x02013; 142)</td><td align="left" rowspan="1" colspan="1">&#x02212;5 (&#x02212;21 &#x02013; 10)</td><td align="left" rowspan="1" colspan="1">103 (87 &#x02013; 146)</td><td align="left" rowspan="1" colspan="1">94 (70&#x02212;127)</td><td align="left" rowspan="1" colspan="1">&#x02212;6 (&#x02212;21 &#x02013; 8)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">gp130 (ng/ml)</td><td align="left" rowspan="1" colspan="1">92&#x000b1;23</td><td align="left" rowspan="1" colspan="1">96 &#x000b1; 23</td><td align="left" rowspan="1" colspan="1">4 (&#x02212;5 &#x02013; 14)</td><td align="left" rowspan="1" colspan="1">91&#x000b1;18</td><td align="left" rowspan="1" colspan="1">97&#x000b1;22</td><td align="left" rowspan="1" colspan="1">6 (&#x02212;3 &#x02013; 15)</td><td align="left" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteoprotegerin (pg/ml)</td><td align="left" rowspan="1" colspan="1">666&#x000b1;243</td><td align="left" rowspan="1" colspan="1">610 &#x000b1; 193</td><td align="left" rowspan="1" colspan="1">&#x02212;56 (&#x02212;127 &#x02013; 16)</td><td align="left" rowspan="1" colspan="1">600&#x000b1;203</td><td align="left" rowspan="1" colspan="1">643&#x000b1;248</td><td align="left" rowspan="1" colspan="1">42 (&#x02212;34 &#x02013; 118)</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Endothelial reactivity</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">vWF (ng/ml)</td><td align="left" rowspan="1" colspan="1">21&#x000b1;14</td><td align="left" rowspan="1" colspan="1">22 &#x000b1; 13</td><td align="left" rowspan="1" colspan="1">1 (&#x02212;3 &#x02013; 5)</td><td align="left" rowspan="1" colspan="1">23&#x000b1;16</td><td align="left" rowspan="1" colspan="1">23 &#x000b1; 12</td><td align="left" rowspan="1" colspan="1">0 (&#x02212;4 &#x02013; 4)</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Matrix turnover</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MMP-9 (ng/ml)</td><td align="left" rowspan="1" colspan="1">247 (50 &#x02013; 386)</td><td align="left" rowspan="1" colspan="1">354 (162 &#x02013; 467)</td><td align="left" rowspan="1" colspan="1">68 (11 &#x02013; 124)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">220 (64 &#x02013; 302)</td><td align="left" rowspan="1" colspan="1">243 (106 &#x02013; 367)</td><td align="left" rowspan="1" colspan="1">13 (&#x02212;33 &#x02013; 59)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">PINP (&#x000b5;g/l)</td><td align="left" rowspan="1" colspan="1">40 (29 &#x02013; 47)</td><td align="left" rowspan="1" colspan="1">40 (27 &#x02013; 50)</td><td align="left" rowspan="1" colspan="1">0 (&#x02212;5 &#x02013; 4)</td><td align="left" rowspan="1" colspan="1">38 (32 &#x02013; 46)</td><td align="left" rowspan="1" colspan="1">45 (37 &#x02013; 68)</td><td align="left" rowspan="1" colspan="1">8 (2 &#x02013; 13)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">PIIINP (&#x000b5;g/l)</td><td align="left" rowspan="1" colspan="1">3.7 (3.3 &#x02013; 4.4)</td><td align="left" rowspan="1" colspan="1">3.8 (3.4 &#x02013; 5.0)</td><td align="left" rowspan="1" colspan="1">0.0 (&#x02212;0.6 &#x02013; 0.5)</td><td align="left" rowspan="1" colspan="1">3.8 (2.9 &#x02013; 4.5)</td><td align="left" rowspan="1" colspan="1">3.8 (3.4&#x02212;5.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.4 &#x02013; 0.8)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>* p &#x0003c; 0.05 for difference between baseline and follow-up. CI: confidence interval; LDL: low density lipoprotein; HDL: high density lipoprotein; NT-proBNP: N-terminal pro-B-type natriuretic peptide; sTNF-R1: soluble tumour necrosis factor receptor 1; MCP-1: monocyte chemotactic protein-1; gp130: Soluble glycoprotein 130; MMP-9: matrix metalloproteinase-9; PINP: procollagen type I N-terminal pro-peptide; PIIINP: procollagen type III N-terminal pro-peptide.</p></fn></table-wrap-foot></table-wrap><p>Among the candidate markers of extracellular matrix remodeling: MMP-9, PINP and PIIINP <xref rid="pone.0089732-DArmiento1" ref-type="bibr">[23]</xref>
<xref rid="pone.0089732-Cicoira1" ref-type="bibr">[24]</xref>
<xref rid="pone.0089732-Zile1" ref-type="bibr">[25]</xref>; PINP and MMP-9 increased significantly throughout the study period for the population as a whole (p &#x0200a;=&#x0200a; 0.03 and 0.03, respectively). Procollagen type I N-terminal pro-peptide increased more in patients treated with rosuvastatin as compared with patients treated with placebo (<xref ref-type="table" rid="pone-0089732-t003">Table 3</xref> and <xref ref-type="fig" rid="pone-0089732-g004">Figure 4</xref>), while for MMP-9 there was a trend toward a more pronounced increase in the placebo group (p &#x0200a;=&#x0200a; 0.08) (<xref ref-type="table" rid="pone-0089732-t003">Table 3</xref>).</p></sec><sec id="s3d"><title>New York Heart Association class and quality of life</title><p>At baseline, 8/43/20 patients were in NYHA class I/II/III, respectively. In the 69 patients who completed the study, the corresponding figures were 12/48/9 at follow-up, indicating a significant improvement (p &#x0200a;=&#x0200a; 0.003). However, no difference was observed between patients treated with rosuvastatin and those treated with placebo (p &#x0200a;=&#x0200a; 0.90). Likewise, quality of life improved significantly in the population as a whole, but adjusted for baseline values, there was no between-group difference at follow-up (<xref ref-type="table" rid="pone-0089732-t002">Table 2</xref>).</p></sec><sec id="s3e"><title>Compliance, safety, and side effects</title><p>In the rosuvastatin arm, two patients, one of whom was later lost to follow-up, prematurely discontinued study drug due to mild side-effects. One patient in the placebo arm stopped taking the study drug after a few days due to stomach pain and diarrhea. Throughout the study period, a total of fifty adverse clinical events were recorded in 33 patients. Twenty-six events were recorded in 16 patients who were allocated to rosuvastatin, and 24 events were recorded in 17 patients allocated to placebo (p &#x0200a;=&#x0200a; 0.80). Four serious adverse events were recorded in four patients allocated to rosuvastatin (surgery for colon cancer; development of atrial fibrillation; hospitalization for worsening HF; and an accidental fracture), and seven serious adverse events occurred in five patients allocated to placebo (development of dementia; and hospitalizations for hypotension, pneumonia, newly developed symptomatic coronary artery disease, and severe nose bleed). There were no episodes of rhabdomyolysis or on-treatment elevation in alanine transaminase. No patient died during follow-up.</p></sec></sec><sec id="s4"><title>Discussion</title><p>Assuming that statins modulate inflammation and the extracellular matrix, we hypothesized that treatment with rosuvastatin would mitigate LV remodeling in patients with DCM. However, we did not find that six months of treatment with this potent statin influenced any measure of LV function or size in our patients. Moreover, while treatment with rosuvastatin was associated with a pronounced reduction in serum cholesterol, it did not affect plasma/serum levels of a wide range of inflammatory variables. The effect on markers of extracellular matrix turnover was modest.</p><p>There is a large body of evidence indicating that inflammation is involved in the pathogenesis of HF <xref rid="pone.0089732-Yndestad1" ref-type="bibr">[26]</xref>. The anti-inflammatory effect of statins has also been extensively studied <xref rid="pone.0089732-Bu1" ref-type="bibr">[27]</xref>. Almost uniformly, an on-treatment fall in CRP has been observed in major statin trials, most of which have been performed in patients with, or at increased risk of, atherosclerotic disease <xref rid="pone.0089732-Ridker1" ref-type="bibr">[2]</xref>
<xref rid="pone.0089732-Crea1" ref-type="bibr">[28]</xref>
<xref rid="pone.0089732-Chan1" ref-type="bibr">[29]</xref>. We have previously demonstrated that the anti-inflammatory effects of these drugs extend beyond a reduction in CRP <xref rid="pone.0089732-Waehre1" ref-type="bibr">[30]</xref>
<xref rid="pone.0089732-Waehre2" ref-type="bibr">[31]</xref>. However, in the present study, rosuvastatin had no effect on markers of inflammation, including CRP.</p><p>The precise mechanisms underlying the proposed anti-inflammatory effect of statins have not been fully elucidated. The so called pleiotropic effects of statins could at least partly involve reduced inflammation secondary to a reduction in LDL levels <xref rid="pone.0089732-Robinson1" ref-type="bibr">[32]</xref>. In our patients, however, we observed a substantial on-treatment decrease in LDL, without this translating to an effect on inflammatory markers. It is possible that the anti-inflammatory effects of statins observed in atherosclerotic disease can be directly attributed to an amelioration of the atherosclerotic burden. However, in a large population of elderly patients with HF of ischemic etiology, rosuvastatin reduced levels of CRP <xref rid="pone.0089732-McMurray1" ref-type="bibr">[33]</xref>, but its effect on other inflammatory markers has been disappointing <xref rid="pone.0089732-Ueland1" ref-type="bibr">[34]</xref>
<xref rid="pone.0089732-Broch1" ref-type="bibr">[35]</xref>
<xref rid="pone.0089732-Askevold1" ref-type="bibr">[36]</xref>. Although the exact mechanism is not clear, it is therefore possible that the ability of statins to modulate inflammation in HF is questionable.</p><p>In the UNIVERSE trial <xref rid="pone.0089732-Krum1" ref-type="bibr">[37]</xref>, assessing the effect of rosuvastatin in DCM, an increase in PIIINP was observed in the rosuvastatin group. The authors speculated that an on-treatment increase in extracellular fibrosis might offset other, potentially beneficial effects of rosuvastatin, explaining the neutral result on LVEF in this study <xref rid="pone.0089732-Ashton1" ref-type="bibr">[38]</xref>. In the present trial, rosuvastatin was associated with an increase in PINP and an attenuated increase in MMP-9, potentially reflecting increased collagen synthesis and inhibited matrix degradation, respectively. While these processes could influence myocardial remodeling, the between-group differences were modest and, in the case of MMP-9, not significant. Most importantly, they were not accompanied by a treatment induced effect on LV function.</p><p>In the population as a whole, we observed a substantial increase in LVEF from baseline to follow-up. Implicitly, our study demonstrates the inherent potential for improvement in patients with DCM, and that adverse remodeling is not an irreversible process. The high degree of spontaneous recovery may have influenced our results. If new treatments for DCM are to prove better than placebo, they will have to not only attenuate adverse remodeling, but also contribute to a marked improvement in LV function.</p><sec id="s4a"><title>Limitations</title><p>The present study was powered to detect a five per cent point difference in LVEF between the two treatment arms. It could be argued that this endpoint was overly ambitious, necessitating a neutral outcome of the trial. On the other hand, we did not observe differences across treatment arms on any measure of LV size or function, including NT-pro-BNP, indicating that rosuvastatin did in fact not impact LV remodeling. Nonetheless, our study was underpowered to detect small, but potentially relevant changes in LV function. Due to the limited number of patients and short observation period, we cannot conclude that statin treatment does not reduce morbidity or mortality in patients with DCM.</p><p>&#x0201c;Idiopathic&#x0201d; DCM is a category that includes different disease entities with a common structural phenotype. While subgroups of these patients might benefit from statin treatment, others may not. This fact may limit the generalizability of our findings.</p><p>Finally, unlike most statins, rosuvastatin is a hydrophilic compound. Accordingly, it has been suggested that it does not have the same pleiotropic profile as the lipid soluble statins <xref rid="pone.0089732-Lipinski1" ref-type="bibr">[11]</xref>, and we cannot exclude that other statins might have performed differently in our patient population. In patients at risk of coronary disease, however, rosuvastatin is highly effective not only when it comes to reducing LDL cholesterol; it also effectively reduces CRP, as well as the number of cardiovascular events and death <xref rid="pone.0089732-Ridker1" ref-type="bibr">[2]</xref>.</p></sec></sec><sec id="s5"><title>Conclusion</title><p>This small, randomized study did not provide evidence that treatment with a potent statin improves LV function in patients with DCM. While safe, rosuvastatin should not be prescribed routinely in patients with HF. Whether treatment with a statin might benefit subgroups of patients with DCM, remains to be elucidated.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0089732.s001"><label>Checklist S1</label><caption><p>
<bold>Consolidated Standards of Reporting Trials (CONSORT) checklist to show that the trial conforms to the CONSORT requirements.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0089732.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0089732.s002"><label>Protocol S1</label><caption><p>
<bold>The full version of the trial protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0089732.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank Dr Rune Mo at the Department of Cardiology, St Olav&#x02019;s Hospital, Trondheim University Hospital, and Else-Marie Christiansen at the Department of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust for their contribution to this work.</p></ack><ref-list><title>References</title><ref id="pone.0089732-Randomised1"><label>1</label><mixed-citation publication-type="journal">
<collab>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)</collab> (<year>1994</year>) <article-title>Lancet</article-title>. <volume>344</volume>: <fpage>1383</fpage>&#x02013;<lpage>1389</lpage>.</mixed-citation></ref><ref id="pone.0089732-Ridker1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Danielson</surname><given-names>E</given-names></name>, <name><surname>Fonseca</surname><given-names>FA</given-names></name>, <name><surname>Genest</surname><given-names>J</given-names></name>, <name><surname>Gotto</surname><given-names>AM</given-names><suffix>Jr</suffix></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein</article-title>. <source>N Engl J Med</source>
<volume>359</volume>: <fpage>2195</fpage>&#x02013;<lpage>2207</lpage>.<pub-id pub-id-type="pmid">18997196</pub-id></mixed-citation></ref><ref id="pone.0089732-Mihos1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Mihos</surname><given-names>CG</given-names></name>, <name><surname>Salas</surname><given-names>MJ</given-names></name>, <name><surname>Santana</surname><given-names>O</given-names></name> (<year>2010</year>) <article-title>The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review</article-title>. <source>Cardiol Rev</source>
<volume>18</volume>: <fpage>298</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">20926939</pub-id></mixed-citation></ref><ref id="pone.0089732-Ridker2"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Rifai</surname><given-names>N</given-names></name>, <name><surname>Clearfield</surname><given-names>M</given-names></name>, <name><surname>Downs</surname><given-names>JR</given-names></name>, <name><surname>Weis</surname><given-names>SE</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events</article-title>. <source>N Engl J Med</source>
<volume>344</volume>: <fpage>1959</fpage>&#x02013;<lpage>1965</lpage>.<pub-id pub-id-type="pmid">11430324</pub-id></mixed-citation></ref><ref id="pone.0089732-Kjekshus1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Kjekshus</surname><given-names>J</given-names></name>, <name><surname>Apetrei</surname><given-names>E</given-names></name>, <name><surname>Barrios</surname><given-names>V</given-names></name>, <name><surname>Bohm</surname><given-names>M</given-names></name>, <name><surname>Cleland</surname><given-names>JG</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Rosuvastatin in older patients with systolic heart failure</article-title>. <source>N Engl J Med</source>
<volume>357</volume>: <fpage>2248</fpage>&#x02013;<lpage>2261</lpage>.<pub-id pub-id-type="pmid">17984166</pub-id></mixed-citation></ref><ref id="pone.0089732-Tavazzi1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Tavazzi</surname><given-names>L</given-names></name>, <name><surname>Maggioni</surname><given-names>AP</given-names></name>, <name><surname>Marchioli</surname><given-names>R</given-names></name>, <name><surname>Barlera</surname><given-names>S</given-names></name>, <name><surname>Franzosi</surname><given-names>MG</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>
<volume>372</volume>: <fpage>1231</fpage>&#x02013;<lpage>1239</lpage>.<pub-id pub-id-type="pmid">18757089</pub-id></mixed-citation></ref><ref id="pone.0089732-Node1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Node</surname><given-names>K</given-names></name>, <name><surname>Fujita</surname><given-names>M</given-names></name>, <name><surname>Kitakaze</surname><given-names>M</given-names></name>, <name><surname>Hori</surname><given-names>M</given-names></name>, <name><surname>Liao</surname><given-names>JK</given-names></name> (<year>2003</year>) <article-title>Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy</article-title>. <source>Circulation</source>
<volume>108</volume>: <fpage>839</fpage>&#x02013;<lpage>843</lpage>.<pub-id pub-id-type="pmid">12885745</pub-id></mixed-citation></ref><ref id="pone.0089732-Sola1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Sola</surname><given-names>S</given-names></name>, <name><surname>Mir</surname><given-names>MQ</given-names></name>, <name><surname>Lerakis</surname><given-names>S</given-names></name>, <name><surname>Tandon</surname><given-names>N</given-names></name>, <name><surname>Khan</surname><given-names>BV</given-names></name> (<year>2006</year>) <article-title>Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure</article-title>. <source>J Am Coll Cardiol</source>
<volume>47</volume>: <fpage>332</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">16412856</pub-id></mixed-citation></ref><ref id="pone.0089732-Wojnicz1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Wojnicz</surname><given-names>R</given-names></name>, <name><surname>Wilczek</surname><given-names>K</given-names></name>, <name><surname>Nowalany-Kozielska</surname><given-names>E</given-names></name>, <name><surname>Szygula-Jurkiewicz</surname><given-names>B</given-names></name>, <name><surname>Nowak</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels</article-title>. <source>Am J Cardiol</source>
<volume>97</volume>: <fpage>899</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">16516598</pub-id></mixed-citation></ref><ref id="pone.0089732-BieleckaDabrowa1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Bielecka-Dabrowa</surname><given-names>A</given-names></name>, <name><surname>Goch</surname><given-names>JH</given-names></name>, <name><surname>Mikhailidis</surname><given-names>DP</given-names></name>, <name><surname>Rysz</surname><given-names>J</given-names></name>, <name><surname>Maciejewski</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy</article-title>. <source>Med Sci Monit</source>
<volume>15</volume>: <fpage>MS12</fpage>&#x02013;<lpage>MS23</lpage>.<pub-id pub-id-type="pmid">19946241</pub-id></mixed-citation></ref><ref id="pone.0089732-Lipinski1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Lipinski</surname><given-names>MJ</given-names></name>, <name><surname>Cauthen</surname><given-names>CA</given-names></name>, <name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name>, <name><surname>Abbate</surname><given-names>A</given-names></name>, <name><surname>Vrtovec</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure</article-title>. <source>Am J Cardiol</source>
<volume>104</volume>: <fpage>1708</fpage>&#x02013;<lpage>1716</lpage>.<pub-id pub-id-type="pmid">19962481</pub-id></mixed-citation></ref><ref id="pone.0089732-Cleland1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Cleland</surname><given-names>JG</given-names></name>, <name><surname>Swedberg</surname><given-names>K</given-names></name>, <name><surname>Follath</surname><given-names>F</given-names></name>, <name><surname>Komajda</surname><given-names>M</given-names></name>, <name><surname>Cohen-Solal</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>The EuroHeart Failure survey programme&#x02014; a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis</article-title>. <source>Eur Heart J</source>
<volume>24</volume>: <fpage>442</fpage>&#x02013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">12633546</pub-id></mixed-citation></ref><ref id="pone.0089732-Elliott1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Elliott</surname><given-names>P</given-names></name>, <name><surname>Andersson</surname><given-names>B</given-names></name>, <name><surname>Arbustini</surname><given-names>E</given-names></name>, <name><surname>Bilinska</surname><given-names>Z</given-names></name>, <name><surname>Cecchi</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases</article-title>. <source>Eur Heart J</source>
<volume>29</volume>: <fpage>270</fpage>&#x02013;<lpage>276</lpage>.<pub-id pub-id-type="pmid">17916581</pub-id></mixed-citation></ref><ref id="pone.0089732-Schulz1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Schulz</surname><given-names>KF</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name> (<year>2010</year>) <article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMC Med</source>
<volume>8</volume>: <fpage>18</fpage>.<pub-id pub-id-type="pmid">20334633</pub-id></mixed-citation></ref><ref id="pone.0089732-Lang1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Lang</surname><given-names>RM</given-names></name>, <name><surname>Bierig</surname><given-names>M</given-names></name>, <name><surname>Devereux</surname><given-names>RB</given-names></name>, <name><surname>Flachskampf</surname><given-names>FA</given-names></name>, <name><surname>Foster</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Recommendations for chamber quantification</article-title>. <source>Eur J Echocardiogr</source>
<volume>7</volume>: <fpage>79</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">16458610</pub-id></mixed-citation></ref><ref id="pone.0089732-Galderisi1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Galderisi</surname><given-names>M</given-names></name>, <name><surname>Henein</surname><given-names>MY</given-names></name>, <name><surname>D'hooge</surname><given-names>J</given-names></name>, <name><surname>Sicari</surname><given-names>R</given-names></name>, <name><surname>Badano</surname><given-names>LP</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes</article-title>. <source>Eur J Echocardiogr</source>
<volume>12</volume>: <fpage>339</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">21555455</pub-id></mixed-citation></ref><ref id="pone.0089732-Rivera1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Rivera</surname><given-names>JM</given-names></name>, <name><surname>Vandervoort</surname><given-names>PM</given-names></name>, <name><surname>Morris</surname><given-names>E</given-names></name>, <name><surname>Weyman</surname><given-names>AE</given-names></name>, <name><surname>Thomas</surname><given-names>JD</given-names></name> (<year>1994</year>) <article-title>Visual assessment of valvular regurgitation: comparison with quantitative Doppler measurements</article-title>. <source>J Am Soc Echocardiogr</source>
<volume>7</volume>: <fpage>480</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">7986545</pub-id></mixed-citation></ref><ref id="pone.0089732-Bollerslev1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Bollerslev</surname><given-names>J</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Jorgensen</surname><given-names>AP</given-names></name>, <name><surname>Fougner</surname><given-names>KJ</given-names></name>, <name><surname>Wergeland</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency</article-title>. <source>Eur J Endocrinol</source>
<volume>154</volume>: <fpage>537</fpage>&#x02013;<lpage>543</lpage>.<pub-id pub-id-type="pmid">16556716</pub-id></mixed-citation></ref><ref id="pone.0089732-Vickers1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Vickers</surname><given-names>AJ</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name> (<year>2001</year>) <article-title>Statistics notes: Analysing controlled trials with baseline and follow up measurements</article-title>. <source>BMJ</source>
<volume>323</volume>: <fpage>1123</fpage>&#x02013;<lpage>1124</lpage>.<pub-id pub-id-type="pmid">11701584</pub-id></mixed-citation></ref><ref id="pone.0089732-Dickstein1"><label>20</label><mixed-citation publication-type="other">Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, <etal>et al</etal>.. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail.</mixed-citation></ref><ref id="pone.0089732-Gullestad1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Gullestad</surname><given-names>L</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Vinge</surname><given-names>LE</given-names></name>, <name><surname>Finsen</surname><given-names>A</given-names></name>, <name><surname>Yndestad</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Inflammatory cytokines in heart failure: mediators and markers</article-title>. <source>Cardiology</source>
<volume>122</volume>: <fpage>23</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">22699305</pub-id></mixed-citation></ref><ref id="pone.0089732-Constans1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Constans</surname><given-names>J</given-names></name>, <name><surname>Conri</surname><given-names>C</given-names></name> (<year>2006</year>) <article-title>Circulating markers of endothelial function in cardiovascular disease</article-title>. <source>Clin Chim Acta</source>
<volume>368</volume>: <fpage>33</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">16530177</pub-id></mixed-citation></ref><ref id="pone.0089732-DArmiento1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>D'Armiento</surname><given-names>J</given-names></name> (<year>2002</year>) <article-title>Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction</article-title>. <source>Trends Cardiovasc Med</source>
<volume>12</volume>: <fpage>97</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">12007733</pub-id></mixed-citation></ref><ref id="pone.0089732-Cicoira1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Cicoira</surname><given-names>M</given-names></name>, <name><surname>Rossi</surname><given-names>A</given-names></name>, <name><surname>Bonapace</surname><given-names>S</given-names></name>, <name><surname>Zanolla</surname><given-names>L</given-names></name>, <name><surname>Golia</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure</article-title>. <source>J Card Fail</source>
<volume>10</volume>: <fpage>403</fpage>&#x02013;<lpage>411</lpage>.<pub-id pub-id-type="pmid">15470651</pub-id></mixed-citation></ref><ref id="pone.0089732-Zile1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Zile</surname><given-names>MR</given-names></name>, <name><surname>Desantis</surname><given-names>SM</given-names></name>, <name><surname>Baicu</surname><given-names>CF</given-names></name>, <name><surname>Stroud</surname><given-names>RE</given-names></name>, <name><surname>Thompson</surname><given-names>SB</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure</article-title>. <source>Circ Heart Fail</source>
<volume>4</volume>: <fpage>246</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">21350055</pub-id></mixed-citation></ref><ref id="pone.0089732-Yndestad1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Yndestad</surname><given-names>A</given-names></name>, <name><surname>Damas</surname><given-names>JK</given-names></name>, <name><surname>Oie</surname><given-names>E</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Gullestad</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Systemic inflammation in heart failure--the whys and wherefores</article-title>. <source>Heart Fail Rev</source>
<volume>11</volume>: <fpage>83</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">16819581</pub-id></mixed-citation></ref><ref id="pone.0089732-Bu1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Bu</surname><given-names>DX</given-names></name>, <name><surname>Griffin</surname><given-names>G</given-names></name>, <name><surname>Lichtman</surname><given-names>AH</given-names></name> (<year>2011</year>) <article-title>Mechanisms for the anti-inflammatory effects of statins</article-title>. <source>Curr Opin Lipidol</source>
<volume>22</volume>: <fpage>165</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">21412153</pub-id></mixed-citation></ref><ref id="pone.0089732-Crea1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Crea</surname><given-names>F</given-names></name>, <name><surname>Monaco</surname><given-names>C</given-names></name>, <name><surname>Lanza</surname><given-names>GA</given-names></name>, <name><surname>Maggi</surname><given-names>E</given-names></name>, <name><surname>Ginnetti</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study</article-title>. <source>Clin Cardiol</source>
<volume>25</volume>: <fpage>461</fpage>&#x02013;<lpage>466</lpage>.<pub-id pub-id-type="pmid">12375804</pub-id></mixed-citation></ref><ref id="pone.0089732-Chan1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Chan</surname><given-names>KY</given-names></name>, <name><surname>Boucher</surname><given-names>ES</given-names></name>, <name><surname>Gandhi</surname><given-names>PJ</given-names></name>, <name><surname>Silva</surname><given-names>MA</given-names></name> (<year>2004</year>) <article-title>HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein</article-title>. <source>Am J Health Syst Pharm</source>
<volume>61</volume>: <fpage>1676</fpage>&#x02013;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">15540478</pub-id></mixed-citation></ref><ref id="pone.0089732-Waehre1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Waehre</surname><given-names>T</given-names></name>, <name><surname>Damas</surname><given-names>JK</given-names></name>, <name><surname>Gullestad</surname><given-names>L</given-names></name>, <name><surname>Holm</surname><given-names>AM</given-names></name>, <name><surname>Pedersen</surname><given-names>TR</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>
<volume>41</volume>: <fpage>1460</fpage>&#x02013;<lpage>1467</lpage>.<pub-id pub-id-type="pmid">12742282</pub-id></mixed-citation></ref><ref id="pone.0089732-Waehre2"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Waehre</surname><given-names>T</given-names></name>, <name><surname>Yndestad</surname><given-names>A</given-names></name>, <name><surname>Smith</surname><given-names>C</given-names></name>, <name><surname>Haug</surname><given-names>T</given-names></name>, <name><surname>Tunheim</surname><given-names>SH</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors</article-title>. <source>Circulation</source>
<volume>109</volume>: <fpage>1966</fpage>&#x02013;<lpage>1972</lpage>.<pub-id pub-id-type="pmid">15051633</pub-id></mixed-citation></ref><ref id="pone.0089732-Robinson1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Robinson</surname><given-names>JG</given-names></name>, <name><surname>Smith</surname><given-names>B</given-names></name>, <name><surname>Maheshwari</surname><given-names>N</given-names></name>, <name><surname>Schrott</surname><given-names>H</given-names></name> (<year>2005</year>) <article-title>Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis</article-title>. <source>J Am Coll Cardiol</source>
<volume>46</volume>: <fpage>1855</fpage>&#x02013;<lpage>1862</lpage>.<pub-id pub-id-type="pmid">16286171</pub-id></mixed-citation></ref><ref id="pone.0089732-McMurray1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>, <name><surname>Kjekshus</surname><given-names>J</given-names></name>, <name><surname>Gullestad</surname><given-names>L</given-names></name>, <name><surname>Dunselman</surname><given-names>P</given-names></name>, <name><surname>Hjalmarson</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis</article-title>. <source>Circulation</source>
<volume>120</volume>: <fpage>2188</fpage>&#x02013;<lpage>2196</lpage>.<pub-id pub-id-type="pmid">19917888</pub-id></mixed-citation></ref><ref id="pone.0089732-Ueland1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Dahl</surname><given-names>CP</given-names></name>, <name><surname>Kjekshus</surname><given-names>J</given-names></name>, <name><surname>Hulthe</surname><given-names>J</given-names></name>, <name><surname>Bohm</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Osteoprotegerin predicts progression of chronic heart failure: results from CORONA</article-title>. <source>Circ Heart Fail</source>
<volume>4</volume>: <fpage>145</fpage>&#x02013;<lpage>152</lpage>.<pub-id pub-id-type="pmid">21216833</pub-id></mixed-citation></ref><ref id="pone.0089732-Broch1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Broch</surname><given-names>K</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Nymo</surname><given-names>SH</given-names></name>, <name><surname>Kjekshus</surname><given-names>J</given-names></name>, <name><surname>Hulthe</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology</article-title>. <source>Eur J Heart Fail</source>
<volume>14</volume>: <fpage>268</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">22302661</pub-id></mixed-citation></ref><ref id="pone.0089732-Askevold1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Askevold</surname><given-names>ET</given-names></name>, <name><surname>Nymo</surname><given-names>S</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Gravning</surname><given-names>J</given-names></name>, <name><surname>Wergeland</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)</article-title>. <source>Circ Heart Fail</source>
<volume>6</volume>: <fpage>91</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">23230311</pub-id></mixed-citation></ref><ref id="pone.0089732-Krum1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Krum</surname><given-names>H</given-names></name>, <name><surname>Ashton</surname><given-names>E</given-names></name>, <name><surname>Reid</surname><given-names>C</given-names></name>, <name><surname>Kalff</surname><given-names>V</given-names></name>, <name><surname>Rogers</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure</article-title>. <source>J Card Fail</source>
<volume>13</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">17338996</pub-id></mixed-citation></ref><ref id="pone.0089732-Ashton1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Ashton</surname><given-names>E</given-names></name>, <name><surname>Windebank</surname><given-names>E</given-names></name>, <name><surname>Skiba</surname><given-names>M</given-names></name>, <name><surname>Reid</surname><given-names>C</given-names></name>, <name><surname>Schneider</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study</article-title>. <source>Int J Cardiol</source>
<volume>146</volume>: <fpage>404</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">20085851</pub-id></mixed-citation></ref></ref-list></back></article>